期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 434, 期 1-2, 页码 453-459出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2012.06.013
关键词
Etoposide; Formulation; Nanoparticles; Rubusoside; Stability; Anti-cancer
资金
- Division Of Materials Research
- Direct For Mathematical & Physical Scien [1005707] Funding Source: National Science Foundation
Etoposide (ETO), a widely used anti-cancer drug, is constrained by its low aqueous solubility and by side effects from both the drug and its solubilizing excipients. In this study, a recently discovered natural solubilizer rubusoside (RUB) was used to achieve the solubilization of ETO. Dynamic light scattering and freeze-fracture transmission electron microscopy studies showed that ETO and RUB formed ETO-RUB nanoparticles (similar to 6 nm in diameter). The powder of ETO-RUB nanoparticles was completely reconstitutable in water and remained stable in this solution at 25 and 37 degrees C for at least 24 h. Under other physiologic conditions, ETO solution was clear and free of precipitation at 25 degrees C, but underwent various structural transformations. In PBS and simulated intestinal fluid, RUB-solubilized ETO underwent epimerization and equilibrated to cis-ETO. In simulated gastric fluid, RUB-solubilized ETO degraded to 4'-demethylepipodophyllotoxin-beta-D-glucoside and 4'-demethylepipodophyllotoxin. Higher temperatures favored epimerization or degradation. Furthermore, a side-by-side comparison with DMSO-solubilized ETO confirmed that the RUB-solubilized ETO showed no significant differences in cytotoxicity in colon, breast and prostate cancer cell lines. RUB effectively solubilized and stabilized etoposide, which sets the stage for further toxicology, bioavailability, and efficacy investigations. (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据